List of Excipients in Branded Drug VENTOLIN HFA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	VENTOLIN HFA	albuterol sulfate	50090-1158	NORFLURANE
DIRECT RX	VENTOLIN HFA	albuterol sulfate	72189-016	NORFLURANE

VENTOLIN HFA Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: August 25, 2026

VENTOLIN HFA is an albuterol sulfate pressurized metered-dose inhaler (pMDI) containing ethanol and HFA-134a propellant. Its commercial differentiation comes primarily from dose consistency, device reliability, supply assurance, regulatory familiarity, and brand recognition rather than from a proprietary excipient system. The core formulation is mature, and generic competition has reduced legal barriers to market entry. The strongest future opportunities are lower-global-warming-potential propellants, device compatibility, suspension stability, manufacturing know-how, and contract supply.

What is the VENTOLIN HFA formulation?

VENTOLIN HFA delivers 90 mcg of albuterol, also known as salbutamol, per actuation. The active ingredient is albuterol sulfate, while the formulation uses ethanol and 1,1,1,2-tetrafluoroethane, commonly called HFA-134a, as inactive ingredients.[1]

Attribute	VENTOLIN HFA profile
Brand owner	GlaxoSmithKline group; marketed in the U.S. by GSK
Active ingredient	Albuterol sulfate
Delivered dose	90 mcg albuterol per actuation
Dosage form	Pressurized metered-dose inhaler
Propellant	HFA-134a
Co-solvent	Ethanol
Canister	18-g canister
Labeled doses	200 actuations
U.S. NDA	021457
Original FDA approval	2001
Therapeutic category	Short-acting beta-2 adrenergic agonist
Primary use	Treatment or prevention of bronchospasm
Biosimilar pathway	Not applicable

The formulation is a suspension or dispersed product system in which micronized albuterol sulfate is delivered through a metering valve and actuator. Ethanol assists formulation wetting, suspension behavior, valve performance and plume characteristics. HFA-134a provides the vapor pressure needed to atomize the dose.

The exact particle engineering, valve configuration, actuator geometry, filling process and manufacturing controls are commercially important even though the listed excipients are few.

What excipients are used in VENTOLIN HFA?

VENTOLIN HFA uses two principal inactive ingredients:

1. HFA-134a propellant.
2. Ethanol co-solvent.

The product does not rely on oleic acid, lecithin or other common suspension stabilizers listed in some inhaled formulations. The limited excipient set simplifies the formulation but increases the importance of physical stability, valve compatibility and particle-size control.

Why ethanol matters

Ethanol has several technical functions:

• Improves wetting of micronized albuterol sulfate.
• Influences suspension settling and redispersion.
• Changes vapor pressure and spray velocity.
• Affects plume geometry and droplet evaporation.
• Supports metering-valve and actuator performance.
• Can influence throat deposition and delivered-dose uniformity.

Ethanol concentration is a critical formulation variable. Increasing or decreasing the level can change particle agglomeration, valve retention, plume temperature, spray force and aerodynamic particle-size distribution. A generic developer cannot treat ethanol as a simple interchangeable solvent.

Why HFA-134a matters

HFA-134a replaced chlorofluorocarbon propellants used in earlier albuterol inhalers. It provides the pressure profile needed for pMDI operation and has long-established pharmaceutical manufacturing and toxicology precedent.[2]

Its principal commercial weakness is environmental. HFA-134a has a high global-warming potential relative to newer propellant candidates. This creates a long-term substitution opportunity for HFA-152a and hydrofluoroolefin-based propellants such as HFO-1234ze(E), subject to pharmaceutical-grade supply, toxicology, device compatibility and regulatory approval.

What excipient strategy supports VENTOLIN HFA performance?

The commercial formulation strategy is based on controlling the interaction among active particles, ethanol, propellant, canister, metering valve and actuator.

Suspension stability

Albuterol sulfate is a crystalline, water-soluble salt that must remain adequately dispersed in the nonaqueous propellant system. Key controls include:

• Micronized particle-size distribution.
• Crystal morphology and surface energy.
• Residual moisture.
• Ethanol content.
• Propellant purity.
• Mixing and filling conditions.
• Container-wall interactions.
• Valve retention and dose recovery.

A formulation that is chemically stable but physically unstable can fail through dose variability, agglomeration, clogging or poor redispersion.

Delivered-dose consistency

The metering valve is as important as the excipient composition. Commercial performance depends on consistent filling of the valve chamber and reproducible release during actuation. Stability testing must evaluate delivered dose at the beginning, middle and end of canister life, including orientation and priming conditions.

The most valuable development data often concern:

• Delivered-dose uniformity.
• Aerodynamic particle-size distribution.
• Fine-particle fraction.
• Spray pattern.
• Plume geometry.
• Valve retention.
• Priming and repriming behavior.
• Temperature cycling.
• Actuation force.
• Canister extractables and leachables.

Device compatibility

HFA-134a, ethanol and albuterol sulfate must remain compatible with the canister coating, valve elastomers, metering components and actuator plastics. Extractables and leachables can create regulatory risk even when the drug and excipient ingredients are individually well known.

A competitor can therefore design around the simple ingredient list while still facing substantial development work on the container-closure system.

What patents protect VENTOLIN HFA?

The principal VENTOLIN HFA formulation is a mature small-molecule product with limited remaining U.S. exclusivity protection. Its historical protection involved the HFA reformulation, aerosol delivery system, manufacturing processes and related product claims rather than a new chemical entity patent on albuterol.

The U.S. Orange Book identifies patents and regulatory exclusivity for approved drug products. For VENTOLIN HFA, the original approval date was 2001, and any early formulation or device patents associated with the product have generally reached their expiration dates or no longer present a meaningful barrier to ordinary U.S. generic entry.[3]

Protection category	Commercial assessment
Albuterol composition patent	Expired or commercially immaterial
HFA reformulation protection	Historical protection; no longer a durable barrier
Formulation patents	Potentially relevant only if a later patent remains listed or is independently enforceable
Metering-valve or actuator patents	May affect specific device designs, but do not necessarily block all generic products
Method-of-use patents	Limited value for conventional rescue-bronchodilator indications
Manufacturing know-how	Still commercially important even where patent protection has expired
Regulatory exclusivity	Expired
Biosimilar exclusivity	Not applicable

Patent analysis must distinguish between a patent that once supported the product launch and a currently enforceable patent that can delay an abbreviated new drug application. Orange Book listings, patent expiration dates and Paragraph IV litigation records should be reviewed by product and jurisdiction rather than inferred from the brand’s age.

When does VENTOLIN HFA lose exclusivity?

VENTOLIN HFA lost the practical benefit of U.S. regulatory exclusivity years ago. FDA approved the product in 2001, and the applicable new-drug exclusivity period has expired.[1]

The product’s current competitive position is therefore based on:

• Brand prescribing familiarity.
• Established clinical use.
• Distribution and reimbursement access.
• Manufacturing scale.
• Device and actuator performance.
• Pharmacy substitution rules.
• Supply reliability.
• Global registrations.

The small-molecule nature of albuterol means that competitors use the ANDA pathway rather than a biosimilar pathway. FDA-approved equivalent products can rely on the reference product’s safety and efficacy findings while demonstrating pharmaceutical equivalence and bioequivalence through the applicable inhalation-product standards.

Which companies are challenging VENTOLIN HFA?

Competition comes from generic albuterol sulfate HFA inhalers and branded alternatives rather than biosimilars.

Competitor type	Product or strategy	Competitive relevance
Generic manufacturers	Albuterol sulfate HFA pMDIs	Price competition and pharmacy substitution
Teva	ProAir HFA and related albuterol products	Established branded and generic respiratory presence
Legacy brands	Proventil and other albuterol products	Historical competition; availability varies
Device companies	pMDI valve and actuator suppliers	Enable generic and reformulated products
Propellant developers	HFA-152a and HFO-1234ze programs	Potential future differentiation
Digital inhaler companies	Sensor-enabled add-ons	Adherence and utilization monitoring rather than direct formulation substitution

FDA approved generic albuterol sulfate inhaler products, including products corresponding to ProAir HFA. The existence of a generic equivalent demonstrates that the basic albuterol HFA product concept is commercially reproducible, even though manufacturing and device performance remain technically demanding.[4]

What is the Orange Book status of VENTOLIN HFA?

VENTOLIN HFA is listed in the FDA Orange Book under NDA 021457. The Orange Book is the relevant source for current patent listings, expiration dates and any regulatory exclusivity associated with the NDA.[3]

A practical diligence review should examine:

1. The current NDA entry.
2. Any listed drug substance, drug product or method-of-use patents.
3. Expiration dates, pediatric extensions and patent-use codes.
4. Whether a proposed generic would require a Paragraph IV certification.
5. ANDA approvals and therapeutic-equivalence ratings.
6. Whether the proposed generic uses the same or a different device configuration.

For a mature albuterol HFA product, the main legal risk generally shifts from basic molecule protection to device patents, formulation-specific claims, manufacturing patents, trade secrets and product liability.

Are there Paragraph IV challenges to VENTOLIN HFA?

Paragraph IV risk is limited by the age of the product and the availability of generic albuterol HFA products. A Paragraph IV certification is relevant only if an ANDA applicant challenges a currently listed patent for the reference product.

Historical challenges may have involved the broader albuterol HFA category or other reference products rather than VENTOLIN HFA specifically. The absence of a current blocking patent does not eliminate litigation risk because a brand owner may assert device, formulation or process patents outside the Orange Book. Those claims typically have less ability to create an automatic statutory stay than a properly listed Orange Book patent.

What formulation patents could protect a next-generation VENTOLIN product?

Future patent value would likely come from a technical improvement rather than from ethanol or HFA-134a alone. Attractive claim areas include:

Low-global-warming propellant systems

A reformulated albuterol pMDI using HFA-152a or HFO-1234ze(E) could support claims covering:

• Propellant composition.
• Ethanol concentration ranges.
• Albuterol particle-size distribution.
• Suspension stability.
• Valve and canister compatibility.
• Filling and manufacturing conditions.
• Delivered-dose and aerodynamic-performance ranges.

A propellant switch is not a simple substitution. HFA-152a and HFO-1234ze(E) have different pressure, density, flammability, solvency and compatibility characteristics. Device redesign, manufacturing-site controls and updated toxicology packages may be required.

Excipient-minimized formulations

A formulation with reduced ethanol or no ethanol could have commercial value if it preserves dose uniformity and aerosol performance. Patentable subject matter could include particle engineering, surface treatment, suspension stabilizers or specific concentration ranges.

Smart inhaler integration

A connected actuator or add-on sensor could be protected separately from the drug formulation. Commercial claims may cover actuation detection, dose counting, adherence monitoring, inhalation technique assessment and data transmission. These systems are more likely to create differentiated reimbursement and service opportunities than to extend the core albuterol patent estate.

What manufacturing and intellectual-property barriers affect generic entry?

The main barriers are operational rather than molecule-based.

Micronization

Albuterol sulfate must meet tight particle-size requirements. Jet milling, fluid-energy milling and related processes can change crystal defects, surface area, electrostatic charge and agglomeration behavior. Process parameters may be protected by trade secrets even when broad patent claims have expired.

Metering valves

Valve chamber volume, elastomer selection, gasket compatibility and dimensional tolerances determine dose reproducibility. A generic product may require a different valve from the reference product while still satisfying pharmaceutical-equivalence requirements.

Canister coatings

Internal coatings can reduce drug adhesion and corrosion but introduce extractables and leachables concerns. Coating chemistry and cure conditions are potential sources of process differentiation.

Filling and supply chain

HFA propellant supply, ethanol pharmaceutical quality, aluminum canisters, valves and actuators must be coordinated. Shortages in any component can disrupt finished-product availability. A supplier with dual-source propellant and valve capacity has commercial value independent of patent ownership.

What commercial opportunities exist in VENTOLIN HFA excipients?

The largest opportunities are adjacent to the branded product.

Opportunity	Commercial rationale	Main barrier
Low-GWP propellant conversion	Supports environmental procurement and future regulatory alignment	Toxicology, flammability, device redesign
Pharmaceutical-grade HFA-152a	Enables next-generation pMDIs	Limited specialized supply and handling requirements
HFO-1234ze(E) systems	Potential lower-climate-impact platform	Formulation and aerosol-performance differences
Ethanol optimization	Can improve suspension and plume performance	Narrow design space and stability risk
Valve-compatible excipient packages	Supports generic and branded pMDI programs	Qualification and extractables testing
Micronized albuterol supply	Required by every albuterol pMDI developer	Particle engineering and scale-up
Contract formulation development	Useful for generic manufacturers and regional brands	Regulatory documentation and device expertise
Canister and actuator systems	Creates recurring component revenue	Supplier qualification and tooling
Connected add-on devices	Adds adherence and utilization services	Reimbursement and user adoption

The most defensible commercial position is a platform that combines propellant, formulation, valve and manufacturing support. Selling ethanol or HFA-134a as commodities provides less differentiation because established suppliers already serve the market.

How does VENTOLIN HFA compare with dry-powder and nebulized albuterol?

VENTOLIN HFA competes with other delivery systems as well as with generic pMDIs.

Delivery system	Strength	Limitation
HFA pMDI	Portable, fast, familiar and relatively inexpensive	Requires actuation-inhalation coordination
Dry-powder inhaler	Breath-actuated and propellant-free	Depends on adequate inspiratory flow
Nebulizer	Useful for patients unable to coordinate a pMDI	Less portable and more time-consuming
Soft-mist inhaler	Slow-moving aerosol and reduced coordination burden	Higher device complexity and cost

Excipient opportunities differ by platform. pMDIs require propellant and valve expertise. Dry-powder products depend on carrier particles, lactose or other powder-engineering approaches. Nebulized products may use aqueous vehicles, tonicity agents and preservatives, depending on the product.

What FDA regulatory issues affect new VENTOLIN-like products?

A new albuterol HFA product generally requires evidence of pharmaceutical equivalence, device performance, delivered-dose uniformity, aerodynamic particle-size distribution, spray pattern, extractables and leachables, and stability. FDA’s orally inhaled and nasal drug product guidance provides the principal development framework.[5]

A low-GWP propellant reformulation may require a new drug application, supplemental application or other regulatory pathway depending on the extent of the change and the relationship to the approved product. The developer must address:

• Propellant toxicology.
• Impurity profile.
• Flammability and handling.
• Container-closure compatibility.
• Comparative aerosol performance.
• Human factors and device instructions.
• Manufacturing controls.
• Environmental impact documentation.

The FDA has encouraged development of products that reduce the environmental impact of metered-dose inhalers while maintaining patient access and clinical performance.[6]

What revenue exposure does VENTOLIN HFA create?

GSK does not generally report VENTOLIN HFA revenue as a separately disclosed line item in its principal public reporting. Product-level revenue exposure is therefore difficult to isolate from broader respiratory and established-pharmaceutical reporting.[7]

The commercial exposure remains meaningful at the category level because albuterol is widely used, but price erosion from generic competition limits the ability of a mature branded pMDI to sustain monopoly pricing. Revenue protection depends on volume, formulary access, international markets, manufacturing efficiency and product continuity.

For excipient and component suppliers, the opportunity is less dependent on VENTOLIN HFA’s brand revenue than on the installed base of albuterol and other pMDI products. A validated low-GWP propellant or valve platform could be supplied across multiple respiratory products.

What patent litigation and settlement issues affect the market?

The principal litigation risk is product-specific. A generic applicant may face claims involving:

• Device geometry.
• Metering-valve construction.
• Suspension formulation.
• Canister coatings.
• Manufacturing processes.
• Labeling and method-of-use language.

Settlements can govern launch dates, authorized-generic rights, supply arrangements or licensing terms. Mature albuterol products have less strategic value for large-scale exclusionary settlements than newer respiratory medicines, but a settlement may still matter if it controls a specific device or formulation patent.

A diligence review should separate:

• Orange Book patent litigation.
• Non-Orange Book patent suits.
• ANDA approval timing.
• Authorized-generic agreements.
• Supply and manufacturing agreements.
• Patent settlements that affect specific strengths or presentations.

Key Takeaways

• VENTOLIN HFA uses albuterol sulfate, ethanol and HFA-134a.
• Its excipient list is short, but aerosol performance depends heavily on particle engineering, valve design, actuator geometry and manufacturing controls.
• The product’s original U.S. exclusivity has expired, and generic albuterol HFA competition is established.
• Biosimilar risk does not apply because albuterol is a small molecule.
• The largest future excipient opportunity is conversion from HFA-134a to a lower-global-warming-potential propellant.
• HFA-152a and HFO-1234ze(E) require new work on pressure, flammability, toxicology, compatibility and device performance.
• Manufacturing know-how remains valuable after broad formulation patents expire.
• Suppliers with integrated propellant, excipient, valve, canister and filling capabilities have the strongest commercial position.
• GSK’s public reporting does not isolate VENTOLIN HFA revenue, making precise brand-level revenue exposure unavailable from standard filings.
• The FDA Orange Book and federal litigation records are the controlling sources for current patent listings and Paragraph IV exposure.

FAQs

Is ethanol in VENTOLIN HFA an active ingredient?

No. Ethanol is an inactive ingredient used as a co-solvent and to influence suspension, valve and aerosol performance.

Can HFA-134a in VENTOLIN HFA be replaced directly with HFA-152a?

No. The propellants have different physical and safety properties. A replacement requires formulation, device, manufacturing, toxicology and regulatory work.

Does VENTOLIN HFA have a biosimilar competitor?

No. Albuterol is a small-molecule drug. Competitors use generic drug pathways, principally ANDAs, rather than biosimilar applications.

Are inhaler excipients patentable after the albuterol patent expires?

Yes. Specific propellant systems, excipient ranges, particle-engineering methods, valve combinations and manufacturing processes can be patentable if they satisfy applicable legal standards.

Is HFA-134a still commercially viable for pharmaceutical inhalers?

Yes. It remains an established pharmaceutical propellant, but its environmental profile creates regulatory, procurement and lifecycle pressure for lower-global-warming-potential alternatives.

References

1. U.S. Food and Drug Administration. (2023). VENTOLIN HFA (albuterol sulfate) inhalation aerosol prescribing information. GlaxoSmithKline LLC.

2. U.S. Environmental Protection Agency. (n.d.). Substitutes in aerosol propellants and refrigeration: HFC-134a. U.S. Environmental Protection Agency.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2020). FDA approves first generic of widely used rescue inhaler, ProAir HFA. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (1998). Guidance for industry: Metered dose inhaler and dry powder inhaler drug products. U.S. Department of Health and Human Services.

6. U.S. Food and Drug Administration. (2022). Considerations for the development of metered dose inhalers with lower global warming potential propellants. U.S. Department of Health and Human Services.

7. GSK plc. (2023). Annual report 2023. London: GSK plc.